Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 3 | MMP-1 | 2754.0 | 67 | |
RA1869 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 3 | MMP-1 | 3972.5 | 44 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 3 | MMP-1 | 562.0 | 37 | |
N2759 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 3 | MMP-1 | 546.0 | 50 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 3 | MMP-1 | 7831.0 | 41 | |
RA1931 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 3 | MMP-1 | 8516.0 | 71 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 3 | MMP-1 | 1753.0 | 49 | |
N2586 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 3 | MMP-1 | 1025.5 | 48 | |
RA1869 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | MMP-1 | 5167.5 | 44 | |
RA1869 | Poly(I:C) | 2 | ug/mL | 3 | MMP-1 | 7180.0 | 35 | ||||
N2759 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | MMP-1 | 1084.0 | 45 | |
N2759 | Poly(I:C) | 2 | ug/mL | 3 | MMP-1 | 1536.5 | 40 | ||||
RA1931 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | MMP-1 | 11192.5 | 46 | |
RA1931 | Poly(I:C) | 2 | ug/mL | 3 | MMP-1 | 7467.5 | 82 | ||||
N2586 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | MMP-1 | 6037.0 | 47 | |
N2586 | Poly(I:C) | 2 | ug/mL | 3 | MMP-1 | 3117.0 | 44 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | MMP-1 | 5178.0 | 59 | |
RA1869 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | MMP-1 | 8231.5 | 56 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | MMP-1 | 438.0 | 47 | |
N2759 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | MMP-1 | 7837.0 | 59 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | MMP-1 | 9457.5 | 54 | |
RA1931 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | MMP-1 | 7009.0 | 38 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | MMP-1 | 1239.0 | 59 | |
N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | MMP-1 | 4385.0 | 64 | |
RA1869 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | MMP-1 | 17959.5 | 50 |